West Pharmaceutical Services, Inc. WST
Set alert
At close · Oct 30
After hours · Oct 30, 4:05 PM ET
- YTD
- +49.97%
- 1 year
- +48.14%
- Open
- 419.06
- Prev close
- 416.67
- Mkt cap
- 28.79B
- Vol
- 1.06M
- Avg vol
- 571.74K
- EPS
- 7.81
- P/E
- 52.83
- Div yield
- 0.25%
More statistics
- Low
- 407.67
- High
- 422.08
- Forward P/E
- 41.31
- Beta
- 0.00
- Short ratio
- 3.38
- Inst. own
- 102.49%
- Dividend
- 1.04
- Ex-div date
- Nov 9, 2026
- Earnings
- Feb 11, 2027
- 50-d avg
- 366.43
- 200-d avg
- 312.69
- 1y target
- 442.20
5D chart
Events in this range
- Oct 29, 2026Earnings: 2.66; estimate 2.2; surprise 20.91%
- Oct 30, 2026Rating: Evercore ISI Group · Outperform → Outperform
- Oct 30, 2026Rating: Barclays · Overweight → Overweight
Signals (123)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:35 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:15 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:05 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:50 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:45 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 9:35 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 4:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:20 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| RSI: Overbought | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 3 days ago |
| RSI: Overbought | Oct 29, 12:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 11:45 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:05 AM | 3 days ago |
| RSI: Overbought | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| RSI: Overbought | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:50 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:00 PM | 5 days ago |
| RSI: Overbought | Oct 27, 11:25 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:15 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 6 days ago |
| RSI: Oversold | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:35 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:25 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:05 AM | 6 days ago |
News
1 day ago marketbeat.com
What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call
West Pharmaceutical Services NYSE: WST reported third-quarter results that exceeded its expectations, driven by continued demand for high-value product components, including those used in GLP-1…
-
2 days ago benzinga.com
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $494
Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $412 to $494.
-
2 days ago benzinga.com
TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $500
TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $420 to $500.
-
2 days ago benzinga.com
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $500.
-
2 days ago benzinga.com
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $480
Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $440 to $480.
3 days ago seekingalpha.com
West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript
West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript
3 days ago zacks.com
West Pharma Q3 Earnings Rise on HVP Strength, 2026 Outlook Raised
WST reports strong Q3 earnings and revenue growth, fueled by high-value products and margin expansion, and raises its 2026 sales and earnings outlook.
3 days ago zacks.com
Compared to Estimates, West Pharmaceutical (WST) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare…
3 days ago benzinga.com
West Pharmaceutical Servs Q3 2026 Earnings Call Transcript
West Pharmaceutical Servs (NYSE:WST) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
3 days ago zacks.com
West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.18 per share. This compares to earnings of $1.96 per share a year…
-
3 days ago benzinga.com
West Pharmaceutical Servs Sees Q4 Adj EPS $2.22-$2.32 vs $2.27 Est; Sees Sales $820.000M-$830.000M vs $826.736M Est
West Pharmaceutical Servs (NYSE:WST) is looking for Q4 Adj EPS of $2.22-$2.32 vs $2.27 analyst estimate. sees sales of $820.000 million-$830.000 million vs $826.736 million analyst estimate.
-
3 days ago benzinga.com
West Pharmaceutical Servs Q3 Adj. EPS $2.66 Beats $2.19 Estimate, Sales $874.500M Beat $825.700M Estimate
West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $2.19 by 21.46 percent. This is a 35.71 percent increase over earnings…
-
3 days ago benzinga.com
West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $9.01-$9.26 to $9.31-$9.41 vs $8.47 Est
West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $9.01-$9.26 to $9.31-$9.41 vs $8.47 analyst estimate..
3 days ago prnewswire.com
West Reports Third-Quarter 2026 Results
Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance EXTON, Pa., Oct. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality…
4 days ago zacks.com
West Pharmaceutical (WST) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of West Pharmaceutical (WST) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the…
5 days ago zacks.com
WST Q3 Earnings Preview: Will HVP Strength Offset Vantage Weakness?
WST's Q3 earnings may benefit from strong HVP demand, biologics and GLP-1 growth, but West Vantage weakness and the SmartDose divestiture could weigh on sales.
1 week ago zacks.com
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical???s biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
1 week ago prnewswire.com
West Declares Quarterly Dividend
EXTON, Pa., Oct. 19, 2026 /PRNewswire/ -- On October 19, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug…
1 week ago benzinga.com
This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History
Ball Corp stock is on an 11-day winning streak, its longest since NYSE trading began in 1973, while the S&P 500 has slipped. Here is what the data shows.
2 weeks ago zacks.com
West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
West Pharmaceutical Services WST shares have gained 36.1% year to date, significantly outperforming its industry's advancement of 7.8%. The rally reflects improving demand for high-value…
2 weeks ago defenseworld.net
West Pharmaceutical Services (NYSE:WST) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
West Pharmaceutical Services, Inc. (NYSE: WST - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving…
2 weeks ago benzinga.com
Meta, JPMorgan, West Pharmaceutical And More: CNBC's ‘Final Trades'
On CNBC's “Halftime Report Final Trades,” Joseph M. Terranova, senior managing director for Virtus Investment Partners, said he likes West Pharmaceutical Services, Inc. (NYSE:WST).
2 weeks ago benzinga.com
Meta, JPMorgan, West Pharmaceutical And More: CNBC’s ‘Final Trades’
CNBC traders picked WST, JPM, META and IYE; analysts raised WST and META targets, while JPM missed Q3 earnings and revenue estimates.
-
2 weeks ago benzinga.com
TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $420
TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $410 to $420.
3 weeks ago seekingalpha.com
Top 50 High-Quality Dividend Growth Stocks For October 2026
I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home…
3 weeks ago prnewswire.com
West to Host Third-Quarter 2026 Conference Call
EXTON, Pa., Oct. 8, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will…
-
3 weeks ago benzinga.com
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.
3 weeks ago seekingalpha.com
West Pharma: Still A Buy, But Expectations Are Rising
West Pharmaceutical Services remains a buy despite a demanding valuation, driven by new growth catalysts and robust financial performance. Double-digit growth from GLP-1s, HVP upgrades, and the…
1 month ago benzinga.com
This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded MetLife, Brinker, Plexus, West Pharma and Omeros, raising ratings and price targets.
-
1 month ago benzinga.com
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400
Morgan Stanley analyst Kallum Titchmarsh upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $365 to $400.
1 month ago zacks.com
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
1 month ago seekingalpha.com
West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago seekingalpha.com
West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
1 month ago defenseworld.net
West Pharmaceutical Services, Inc. $WST Shares Sold by HB Wealth Management LLC
HB Wealth Management LLC lowered its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 28.3% in the second quarter, according to its most recent filing with the Securities and…
-
1 month ago benzinga.com
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415
UBS analyst Doug Schenkel maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $340 to $415.
-
3 months ago benzinga.com
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412
Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $400 to $412.
-
3 months ago benzinga.com
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425
Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $410 to $425.
3 months ago benzinga.com
West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum
West Pharmaceutical reported Q2 earnings and revenue beat, higher 2026 guidance, and continued strength in GLP-1 and HVP products.
3 months ago benzinga.com
Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call
West Pharmaceutical Servs (NYSE:WST) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs…
3 months ago benzinga.com
Earnings Scheduled For July 23, 2026
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is…
-
3 months ago benzinga.com
West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 Est; Raises FY2026 Sales Guidance from $3.295B-$3.350B to $3.345B-$3.380B vs $3.332B Est
West Pharmaceutical Servs (NYSE:WST) raises FY2026 Adj EPS guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 analyst estimate. Raises FY2026 sales outlook from $3.295 billion-$3.350 billion to $3.345…
-
3 months ago benzinga.com
West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 Est
West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 analyst estimate..
-
3 months ago benzinga.com
West Pharmaceutical Servs Sees Q3 Adj EPS $2.14-$2.24 vs $2.12 Est; Sees Sales $820.000M-$835.000M vs $815.707M Est
West Pharmaceutical Servs (NYSE:WST) is looking for Q3 Adj EPS of $2.14-$2.24 vs $2.12 analyst estimate. sees sales of $820.000 million-$835.000 million vs $815.707 million analyst estimate.
-
3 months ago benzinga.com
West Pharmaceutical Servs Q2 Adj. EPS $2.37 Beats $2.08 Estimate, Sales $872.300M Beat $838.586M Estimate
West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $2.08 by 13.94 percent. This is a 28.8 percent increase over earnings…
-
3 months ago benzinga.com
West Pharmaceutical Services Enters Into Multiple Amended Distribution And Crosslicensing Agreements With Daikyo Seiko
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000105770/000010577026000093/wst-20260714.htmThe terms of the Agreements are substantially similar to the terms of the Amended and Restated Technology…
-
3 months ago benzinga.com
BNP Paribas Initiates Coverage On West Pharmaceutical Servs with Outperform Rating, Announces Price Target of $447
BNP Paribas analyst Curtis Moiles initiates coverage on West Pharmaceutical Servs (NYSE:WST) with a Outperform rating and announces Price Target of $447.
-
3 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $365
Morgan Stanley analyst Kallum Titchmarsh maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target from $325 to $365.
-
3 months ago benzinga.com
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $410
Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $390 to $410.
-
4 months ago benzinga.com
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $390
Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $350 to $390.
4 months ago benzinga.com
This Brady Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Wall Street analysts upgraded AJG & BRC. See analyst rating changes & how they view BRC stock.